Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

NCT06312644 is registered in ClinicalTrials.gov with Alexion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT06312644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06312644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Lead sponsor
Alexion Pharmaceuticals, Inc.
Phase
Observational
Overall status
Recruiting
Start date
December 16, 2024
Completion date
July 11, 2034
Enrollment
75 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

atypical hemolytic uremic syndrome (ahus), generalized myasthenia gravis (gmg), neuromyelitis optica spectrum disorder (nmosd), paroxysmal nocturnal hemoglobinuria (pnh), pregnancy, ultomiris-exposed pregnant/ postpartum